ABSTRACT Many studies in acute severe asthma have had low power. Fifteen randomised double blind studies investigating the treatment of acute severe asthma published during 1974-84 were analysed for power and 95% confidence limits. Twelve studies failed to detect a significant difference in bronchodilatation produced by two treatments and reported the treatments to produce equal effect. Each study had, however, less than a 60% probability of detecting a true 25% difference in bronchodilatation. studies with negative results showed that because of low power most had a considerable chance of not being able to detect a clinically useful difference between treatments (type II error).7
The surprisingly few double blind studies comparing treatments in acute severe asthma have reported disparate results. The treatments studied have included corticosteroids, sympathomimetics, and aminophylline. The place of corticosteroid treatment is unclear. Many studies have claimed that no benefit follows but Macdonald and others have recommended the use of corticosteroids.1 2 While there is no doubt that sympathomimetic drugs are life saving in severe asthma there is argument about the best route of administration. Theoretically sympathomimetics such as salbutamol might be expected to produce better bronchodilatation when given parenterally than by inhalation, but reports suggest that this is not the case. 34 Investigators have also made varying claims about aminophylline, some reporting it to be extremely useful, others preferring not to use it.5 6 How may these differing statements be explained, and how should we investigate the treatment of severe asthma in the future? Trials so far have concentrated on tests of statistical significance. Although the familiar expression p < 0-05 means that the observed difference between treatments could arise by chance in less than one in 20 trials (type I error), a nonsignificant difference between treatments does not mean that the treatments produce the same result. Whether trials reporting no difference between treatment regimens were ever likely to demonstrate a difference (their power) depends on their design and the number of patients studied. A recent review of 71 studies with negative results showed that because of low power most had a considerable chance of not being able to detect a clinically useful difference between treatments (type II error). 7 Many workers have compared two treatments in severe asthma and on finding "no significant" difference (p > 005) between the results of treatment have concluded that the treatments produce equal effect. To assess the outcome of reported trials in severe asthma I have analysed double blind randomised studies comparing one treatment with another in terms of the statistical significance of any differences observed, 95% confidence limits for the results of treatment, and the power of the study to detect a real difference between treatments.
Methods
Twenty two trials investigating the use of corticosteroid drugs or intravenous bronchodilators in the treatment of acute severe asthma published during 1974-84 were identified through Index Medicus. Fifteen were randomised, controlled, and double blind and the results of these have been analysed. In each study the bronchodilator response, measured by increase (mean and standard deviation) in peak expiratory flow rate (PEF) or FEV1, was noted along with the study size and level of significance recorded in the paper. One study reported PEF and FEV, and both were analysed.
If D are related to the vertical scale of f-that is, the probability of making a false negative error.
Percentage difference between treatments was calculated as follows. Nebulised treatment produced a 44% increase in PEF and for intravenous treatment 826 to produce 25% more bronchodilatation it would have to increase the PEF by 69%: an increase of 59 1 min-, which means a difference of 21 I minfrom that produced by nebulised treatment alone. This example shows that the study design used would result in a 95% (f = 0 95) probability of a conclusion of no significant difference when the actual difference was 21 Imin-' (a 25% difference between treatments) and a 72% probability of showing no difference when the actual difference was 42 1 mint (a 50% difference between treatments). Ninety five per cent confidence limits were also determined on the basis of the difference between mean responses cited, the standard deviation, and the number of patients studied.
Results

TRIALS COMPARING CORTICOSTEROID WITH PLACEBO
There were five studies of the use of corticosteroids in severe asthma. Four of these were unable to detect a statistically significant benefit from the treatment.9-12 These studies, however, all had less than a 60% (power 0 3-0 6) probability of detecting 25% more bronchodilatation in those treated with corticosteroid. None of the trials would have been likely to miss a true 50% difference in bronchodilatation caused by the treatments (table 1) . The 95% confidence limits for the studies are shown in figure 2 . The four negative studies, being unable to detect a significant benefit from corticosteroid treatment, have limits crossing the midline zero point. Four of the five studies, however, reported more bronchodilatation in those treated with corticosteroid but only one recorded a statistically significant difference.13 In this case the 95% confidence limits lie in favour of steroid treatment and do not cross the zero line. The power of this study was, however, no greater than the others, its significance being related only to the large difference in response seen.
COMPARISONS OF INTRAVENOUS AND NEBULISED SYMPATHOMIMETIC TREATMENT
Two randomised double blind studies have compared nebulised and intravenous salbutamol. 4 14 Neither study detected a significant difference between treatments. Examination of the PEF data in the studies, however, shows that they had less than a 50% (power 0 3, 0 5) probability of being able to detect a true 50% difference in increase in PEF produced by the treatments. One study also reported the results in terms of FEV1 and the power of this study to detect a true 25% difference was 0 5. It had little probability of missing a 50% difference in bronchodilatation (table 1) The 95% confidence limits are shown in figure 3 . Although all cross the midline, the limits are wide and substantial differences in favour of intravenous treatment are still possible. produce equal effect. The failure to attain a level of statistical significance, however, does not necessarily ither salbutamol or isoprenaline with amino-mean that two treatments being compared are identiihylline.5 6 15 In two no difference was reported cal. The 12 studies had less than a 60% probability of )etween treatments but both of these had a large type detecting a true 25% difference in treatments. I error, having less than a 30% (power 0 1, 0-3)
There has been much debate concerning the use of wrobability of detecting a true 25% difference in corticosteroids in severe asthma and, although the *esponse to the treatments (table 1) . The third study studies reported no benefit from the treatment, it is *eported significantly more bronchodilatation in clear that they had large type II error and may have 'hose treated with inhaled isoprenaline (fig4).
been unable to detect a clinically useful difference. Although differences were not statistically significant, given improved results equalling the effect of the combination is left unanswered by these studies. Different doses of drug were used in the studies referred to and this makes direct comparisons of results difficult. In most cases, however, the doses used were comparable (table 2) .
Future trials comparing treatment regimens in severe asthma need to take the type II error into account and negative studies in particular should include an analysis of the power attained in the study together with 95% confidence limits for the results. It is preferable to plan the requirements of a study in advance. The nomogram published by Altman may be used to calculate the power of a proposed study.8
An estimate of standard deviation of PEF or FEV1 for the group to be studied is used to calculate the number of patients required to give a desired probability of detecting a clinically useful difference between treatments. Because patients recover from attacks of severe asthma at very different rates the increase in PEF varies widely from patient to patient and its standard deviation is considerable. For a study to reach a significant result therefore large numbers of patients need to be investigated. The power of a study may be increased by studying a more homogeneous population, such as those known to respond poorly to initial treatment.
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